MultiCell has focused its technologies on four disease targets: multiple sclerosis (MS); type-1 diabetes; and infectious disease. The Company’s therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapse-remitting MS; MCT-275, for the treatment of type-1 diabetes; and MCT-465, addressing influenza A infection. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery and for the production of therapeutic proteins.
MultiCell Technologies is a dynamic growth company offering prospective employees the opportunity to work with leading-edge technologies to develop therapeutics for the treatment of important diseases.
For employment inquiries, please contact hr_dept@multicelltech.com.
MultiCell Research & Development Headquarters
701 George Washington Highway
Lincoln, RI 02865
401.333.0610 Office
info@multicelltech.com
MultiCell Technologies, Inc. Corporate Headquarters
701 George Washington Highway
Lincoln, RI 02865
401.333.0610 Office
401.333.0659 Fax
info@multicelltech.com
MultiCell Investor Relations
MultiCell Corporate Headquarters
401.333.0610
MCETinvestor@Multicelltech.com
MultiCell ImmunoTherapeutics Inc.
9710 Scranton Rd., Suite 170
San Diego, CA 92121
858.200.0598
info@multicelltech.com
